Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia
NCT ID: NCT05759052
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
467 participants
OBSERVATIONAL
2023-05-12
2025-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this cross-sectionnal study will be to explore the CIPN prevalence and severity in adult survivors of childhood leukemia and having been treated by vincristine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies
NCT03854864
Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients
NCT03430674
Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT03272919
Prevention of Chemotherapy-Related Polyneuropathy Via Sensorimotor Exercise Training
NCT02871284
Whole-body Vibration Training to Reduce the Symptoms of Chemotherapy-induced Peripheral Neuropathy
NCT03032718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Thereafter patients will received a self-administered questionnaire exploring the chemotherapy-induced peripheral neuropathy and related comorbidities (pain, neuropathic pain, anxiety, depression, health-related quality of life, substance use, physical activity, deprivation). Oncological and sociodemographic characteristics of participants will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort of adult survivors having been treated by vincristine
Cohort of adult survivors having been treated by vincristine for a childhood leukemia
self-administered questionnaire
Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
self-administered questionnaire
Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Active oncological pathology
* Current cancer treatment
* Adults protected
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Balayssac
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01758-35
Identifier Type: OTHER
Identifier Source: secondary_id
PHRC IR 2021 BALAYSSAC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.